Antiarrhythmic actions of meptazinol, a partial agonist at opiate receptors, in acute myocardial ischaemia

British Journal of Pharmacology
O FagbemiL Szekeres


1 The intravenous administration, to anaesthetized rats, of meptazinol (1 and 2 mg kg-1), a partial agonist at opiate receptors, greatly reduced the incidence of ventricular extrasystoles that resulted from acute coronary artery occlusion. The incidence of ventricular fibrillation (VF) was reduced from 50% (in the controls) to 10% and the mortality from 30% to zero. 2 In similar doses, pretreatment with meptazinol also reduced ventricular arrhythmias, including fibrillation, in conscious rats subjected to coronary artery occlusion. In this model, survival at 16 h was increased from 27% in the controls to 50% and 83% respectively in rats pretreated with 1 and 2 mg kg-1 of the drug. 3 In antiarrhythmic doses, meptazinol had little effect on either heart rate or systemic arterial blood pressure. 4 Intracellular action potential recordings from papillary muscle removed from rats given meptazinol (2 mg kg-1) 15 min previously showed an increase in APD50 and APD90 of more than 40%. There was no effect on dV/dtmax. When superfused with meptazinol in vitro normal rat papillary muscle stimulated at 1 or 3 Hz showed an increase in APD90 and a decrease in dV/dtmax. 5 The antiarrhythmic effect of meptazinol in these models can probably be ...Continue Reading


Jun 1, 1979·British Journal of Anaesthesia·C JordanJ G Jones
Jan 1, 1979·General Pharmacology·S Rashid, J F Waterfall
Aug 1, 1970·British Journal of Pharmacology·B N Singh, E M Vaughan Williams
Aug 1, 1982·British Journal of Pharmacology·O FagbemiL Szekeres


Oct 14, 1986·European Journal of Pharmacology·S W Rabkin, O Roob
Nov 1, 1995·Clinical and Experimental Pharmacology & Physiology·Leonid N Maslov, Y B Lishmanov
Mar 1, 1990·Pharmacology & Toxicology·K G Helgesen, H Refsum
Mar 1, 1992·The Journal of Pharmacy and Pharmacology·S AlarcónM L Laorden
Sep 1, 1993·Archives of Emergency Medicine·J A Chambers, H R Guly
Jul 1, 1989·British Journal of Pharmacology·G Boachie-AnsahJ Parratt
Apr 1, 1986·British Journal of Pharmacology·J Parratt, R Sitsapesan
Aug 1, 1991·Biulleten' eksperimental'noĭ biologii i meditsiny·Leonid N Maslov, Iu B Lishmanov
Feb 21, 2014·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Leonid N MaslovJian-Ming Pei
Sep 20, 2018·Non-coding RNA·Zesergio MeloRaquel Echavarria
May 21, 2016·Medicinal Research Reviews·Leonid N MaslovJames M Downey

Related Concepts

Nerve Impulses
Anesthesia Procedures
Cardiac Depressants
Cardiac Arrhythmia
Coronary Heart Disease
August Rats
Opioid Receptor

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.


Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.